Mission Therapeutics

🎉 15th Anniversary of TREAT-NMD's Advisory Committee for Therapeutics (TACT)! 🎉   Join our Chief Scientific Officer Paul Thompson and Principal Scientist Ciarán Fealy at the first ever symposium presented by TREAT-NMD’s Advisory Committee for Therapeutics (#TACT).   TREAT-NMD (#NeuroMuscularDisease) is a global network of experts in the #neuromuscular field with the common goal of accelerating the development of effective treatments and establishing the best diagnosis and care for people with living with #NMD.   TACT's ‘Developing Therapies in Rare Neuromuscular Disease’ symposium, a day-long event jam-packed with exclusive talks and interactive sessions, will take place in Boston, Massachusetts, on October 31st.   🤝Connect with Paul and Ciarán onsite to learn more about Mission’s #mitophagy targeting pipeline of de-ubiquitylating enzyme (DUB) inhibitors for treating conditions driven by a build-up of dysfunctional #mitochondria in cells, including #DuchennesMuscularDystrophy (#DMD), #ParkinsonsDisease, #Alzheimers, #CardioRenalDiseases, #heartfailure and #IPF.   #DUBinhibitors #Parkinsons

📢 It’s World Mitochondrial Disease Week! 📢   Join Mission Therapeutics during #WorldMitoWeek2024 in raising awareness and understanding of mitochondrial diseases.   The term mitochondrial disease usually refers to a set of devastating genetic diseases, which collectively affect around 1 in 5,000 people.   However, on a broader level, mitochondrial dysfunction is a significant driver of more common diseases including: #ParkinsonsDisease (PD), #alzheimers, #DuchennesMuscularDystrophy (#DMD), #cardiorenaldiseases, #heartfailure, and #IPF.   Mitochondria, often referred to as the powerhouse of the cell, play a pivotal role in energy production but they are also involved in a wide array of other vital tasks including cell-to-cell signalling and apoptosis (programmed cell death).   This year’s awareness week theme, ‘Illuminate Tomorrow: Revitalise your energy’ aims to shine a light🔦on ways mitochondrial diseases can be tackled and the challenges faced by people with them.   Learn more about Mission's novel drug candidates which aim to improve the health of cells’ mitochondria by boosting a process called #mitophagy, using the link in the first comment below👇   We currently have candidate drugs in clinical trials for Parkinsons Disease and cardio renal disease.   #IlluminateTomorrow #DUBInhibitors #parkinsons #alzheimersdisease

Tomorrow, our CEO Anker Lundemose will be at the Annual Seed🌱 Summit, the premier event welcomes portfolio companies, investors and pharma BD from across Europe and US for a full day of networking and discussions around company creation at the Novo Holdings HQ in Copenhagen. Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria which are significant drivers of disease pathophysiology in #acutekidneyinjury (#AKI), #ParkinsonsDisease (PD), #heartfailure, #DuchennesMuscularDystrophy (#DMD), #IPF, mitochondrial diseases and #alzheimers. Keep up to date with Mission Therapeutics by following us at Mission Therapeutics on LinkedIn or @MISSIONTherapeu on X / Twitter. You can also visit our website using the link in the comments below. #NovoHoldings #mitophagy #DUBInhibitors #parkinsons #alzheimersdisease

Our VP of Pharmacology, Sarah Almond has been featured in ADLIB Recruitment | B Corp™ ’s Women in Science blog series. Sarah spoke with🎙Jazz Jones, Senior Recruitment Consultant at ADLIB, about the challenges she’s faced throughout her career in #drugdiscovery and offers empowering advice for the next generation of #WomenInScience. Learn more about Sarah here 👉 https://bit.ly/3LArA4k

Mission Therapeutics is thrilled to announce that it has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (#MJFF) and Parkinson’s UK. The funding will support the clinical development of #MTX325, a potential disease-modifying treatment for Parkinson’s.   We are honoured that the The Michael J. Fox Foundation for Parkinson's Research continues to support Mission Therapeutics and delighted that Parkinson's UK has joined us in our endeavour.   The Michael J. Fox Foundation is dedicated to accelerating the development of next generation treatments.   Driven by people with #parkinsons community, Parkinsons UK funds research on the most promising treatments, whereas, its global drug and discovery programme, Parkinson’s Virtual Biotech, is designed to bridge the gap between exciting discoveries and promising ideas for new therapies forward.   Mission Therapeutics is committed to advancing its pipeline of deubiquitylating enzyme (#DUBs) inhibitor drug candidates for conditions driven by a build-up of dysfunctional mitochondria in cells, including #ParkinsonsDisease, #HeartFailure #KidneyDisease #DuchennesMuscularDystrophy (#DMD), #idiopathicpulmonaryfibrosis (#IPF) and #Alzheimers.   To learn more about the funding, use the link in the comments below.   #DUBinhibitors #neurodegenerativediseases 

Our CEO Anker Lundemose spoke to Megan Thomas from Drug Discovery World about exploring new frontiers in Parkinson’s Disease. Anker provided insight on the intersection of AI-assisted drug development and the search for next generation treatments for #parkinsons.   Read the full article here: https://bit.ly/3LkQvJ3   #neurodegenerativediseases #mitophagy #DUBInhibitors

Laura Parton, our Senior Director of Project Management, will be presenting at the 2024 BioBabraham Campus Symposium. Laura will present on the development of Mission's USP30 inhibitor #MTX325, a potentially disease-modifying treatment for #ParkinsonsDisease, which is currently undergoing clinical trials. 📅 Wednesday, June 26th 🕒 15:40 – 17:15 📍 Babraham Research Campus To learn more about Mission's pipeline of novel mitophagy-targeting de-ubiquitylation (DUB) enzyme inhibitor drug candidates, use the link in the comments below. The BioBabraham Symposium is a joint enterprise between The Babraham Institute and the Babraham Research Campus that brings together the academic and commercial sectors of the community to showcase the remarkable scientific innovation taking place on Campus. #neurodegenerativediseases #mitophagy #DUBInhibitors

Mission Therapeutics is headed to Finland! Join our Chief Scientific Officer Paul Thompson at the 10th European Academy of Neurology Congress in Helsinki from June 29th – July 2nd! Mission’s asset, #MTX325, a potentially disease-modifying treatment for #parkinsonsdisease (PD) is currently undergoing Phase I clinical trials in healthy volunteers. Reach out to if you'd like to connect with Paul to learn more about MTX325 and Mission’s #mitophagy targeting pipeline of de-ubiquitylation enzyme (DUB) inhibitors. The Congress is Europe’s biggest forum for #neurology, bringing together thousands of industry professionals from all over the world to network and collaborate on solutions to tackle major challenges in neurology. #EAN2024 #HomeOfNeurology #EANeurology #10yearsEAN #parkinsons #DUBinhibitors

Mission Therapeutics is #hiring! We have a great opportunity for a Research Scientist to join the Mission team as we continue to discover and develop novel #smallmolecule therapeutics to combat serious diseases including #ParkinsonsDisease by enhancing #mitophagy – the vital quality control process cells use to ensure dysfunctional mitochondria are removed. If you are interested in joining our talented team and working in a stimulating and inspiring environment, please send your CV, along with a covering letter to recruitment@missiontherapeutics.com For the full job description, use the link in the first comment below. #DUBinhibitors #neurodegenerativediseases #biotech #drugdiscovery

Don’t miss the opportunity to connect with our CEO Anker Lundemose at #BioEquity Europe 2024, from 12 - 14 May in San Sebastian, Spain! It’s an ideal time to meet as the clinical trial for our lead asset #MTX325 is now underway. MTX325, is a potentially disease-modifying treatment for #Parkinsons Disease, a progressive neurological condition that affects over 10 million people worldwide. 📧 Hear the latest developments on Mission Therapeutics’ innovative #mitophagy targeting pipeline in a 1-1 meeting using the link in the comments below. @Mission Therapeutics is committed to advancing its pipeline of deubiquitylating enzyme (#DUBs) inhibitor drug candidates for conditions driven by a build-up of dysfunctional mitochondria in cells, including #ParkinsonsDisease, #HeartFailure, #KidneyDisease, #DuchennesMuscularDystrophy (#DMD), #idiopathicpulmonaryfibrosis (#IPF) and #Alzheimers. #BioEquityEurope #BioEquity2024